Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 138209 | 4.015 |
09:34 ET | 42812 | 3.94 |
09:36 ET | 304487 | 3.93 |
09:38 ET | 44953 | 3.91 |
09:39 ET | 36463 | 3.87 |
09:41 ET | 20713 | 3.9 |
09:43 ET | 92466 | 3.905 |
09:45 ET | 56289 | 3.905 |
09:48 ET | 34870 | 3.88 |
09:50 ET | 21686 | 3.865 |
09:52 ET | 104343 | 3.895 |
09:54 ET | 36166 | 3.885 |
09:56 ET | 22036 | 3.91 |
09:57 ET | 22430 | 3.91 |
09:59 ET | 63263 | 3.8877 |
10:01 ET | 64036 | 3.915 |
10:03 ET | 19205 | 3.88 |
10:06 ET | 15648 | 3.885 |
10:08 ET | 21990 | 3.8629 |
10:10 ET | 21065 | 3.855 |
10:12 ET | 115311 | 3.84 |
10:14 ET | 28587 | 3.845 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -11.1x | --- |
Vera Therapeutics Inc | 2.1B | -19.4x | --- |
CG Oncology Inc | 2.2B | -31.1x | --- |
Celldex Therapeutics Inc | 2.2B | -11.5x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.7x | --- |
Agios Pharmaceuticals Inc | 2.1B | -7.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 4,049.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.